Evidence map›Paper›PMID 29133360›Full record

ArticleHypertension (Dallas, Tex. : 1979)2018

Selective Nanoparticle Targeting of the Renal Tubules.

Ryan M Williams, Janki Shah, Helen S Tian, Xi Chen, Frederic Geissmann, Edgar A Jaimes, Daniel A Heller

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hypertension (Dallas, Tex. : 1979), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 1 synthesis or guideline pooled it, 122 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ryan M WilliamsFrom the Memorial Sloan Kettering Cancer Center, New York (R.M.W., J.S., H.S.T., X.C., F.G., E.A.J., D.A.H.); University of Massachusetts Medical School, Worcester (H.S.T.); and Weill Cornell Medical College, New York (X.C., F.G., E.A.J., D.A.H.).
Janki ShahFrom the Memorial Sloan Kettering Cancer Center, New York (R.M.W., J.S., H.S.T., X.C., F.G., E.A.J., D.A.H.); University of Massachusetts Medical School, Worcester (H.S.T.); and Weill Cornell Medical College, New York (X.C., F.G., E.A.J., D.A.H.).
Helen S TianFrom the Memorial Sloan Kettering Cancer Center, New York (R.M.W., J.S., H.S.T., X.C., F.G., E.A.J., D.A.H.); University of Massachusetts Medical School, Worcester (H.S.T.); and Weill Cornell Medical College, New York (X.C., F.G., E.A.J., D.A.H.).
Xi ChenFrom the Memorial Sloan Kettering Cancer Center, New York (R.M.W., J.S., H.S.T., X.C., F.G., E.A.J., D.A.H.); University of Massachusetts Medical School, Worcester (H.S.T.); and Weill Cornell Medical College, New York (X.C., F.G., E.A.J., D.A.H.).
Frederic GeissmannFrom the Memorial Sloan Kettering Cancer Center, New York (R.M.W., J.S., H.S.T., X.C., F.G., E.A.J., D.A.H.); University of Massachusetts Medical School, Worcester (H.S.T.); and Weill Cornell Medical College, New York (X.C., F.G., E.A.J., D.A.H.).
Edgar A JaimesFrom the Memorial Sloan Kettering Cancer Center, New York (R.M.W., J.S., H.S.T., X.C., F.G., E.A.J., D.A.H.); University of Massachusetts Medical School, Worcester (H.S.T.); and Weill Cornell Medical College, New York (X.C., F.G., E.A.J., D.A.H.).
Daniel A HellerFrom the Memorial Sloan Kettering Cancer Center, New York (R.M.W., J.S., H.S.T., X.C., F.G., E.A.J., D.A.H.); University of Massachusetts Medical School, Worcester (H.S.T.); and Weill Cornell Medical College, New York (X.C., F.G., E.A.J., D.A.H.). hellerd@mskcc.org.
University of Massachusetts Chan Medical School · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Summer research experiences for medical students supervised by faculty mentorsR25CA020449 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Charlotte Eielson Ariyan · 1985 to 2026
$6.2M
Macrophage development and specification in mice.R01AI130345 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI Frederic Geissmann · 2017 to 2026
$5.7M
P-selectin-Mediated Targeting of PI3K Nanomedicines to the Tumor MicroenvironmentR01CA215719 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI HELLER, DANIEL ALAN · 2018 to 2022
$3.1M
Lineages and pathophysiology of clonal histiocytic disordersR01HL138090 · NHLBI · SLOAN-KETTERING INST CAN RESEARCH · PI GEISSMANN, FREDERIC · 2017 to 2020
$2.9M
Transient Metabolite Detection for Single-Cell Metabolomics and DiagnosticsDP2HD075698 · NICHD · SLOAN-KETTERING INST CAN RESEARCH · PI HELLER, DANIEL ALAN · 2012 to 2012
$2.7M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA215719NCI NIH HHS R25 CA020449NHLBI NIH HHS R01 HL138090NIAID NIH HHS R01 AI130345NICHD NIH HHS DP2 HD075698
6 · The paper itself

Abstract

Direct targeting to the kidneys is a promising strategy to improve drug therapeutic index for the treatment of kidney diseases. We sought to investigate the renal selectivity and safety of kidney-targeted mesoscale nanoparticle technology. We found that direct intravenous administration of these particles resulted in 26-fold renal selectivity and localized negligibly in the liver or other organs. The nanoparticles targeted the renal proximal tubular epithelial cells, as evidenced by intravital microscopy and ex vivo imaging. Mice treated with the nanoparticles exhibited no negative systemic consequences, immune reaction, liver impairment, or renal impairment. The localization of material selectively to the renal tubules is uncommon, and this work portends the development of renal-targeted drugs for the treatment of kidney diseases.

Indexed as

Kidney DiseasesKidney Tubules, ProximalNanoparticlesAdministration, IntravenousAnimalsDose-Response Relationship, DrugDrug Delivery SystemsImmune SystemMiceMicroscopy, FluorescenceRenal EliminationTissue Distributionbiomaterialsdrug carrierskidneynanoparticlespharmacokinetics

Identifiers

PMID29133360
PMCPMC5730475
OpenAlexW2770786260

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.